Citadel Advisors’s GenMark Diagnostics, Inc GNMK Stock Holding History

Citadel Advisors’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-29,800	Closed	-$712K	–	14976
2021 Q1	$712K	Sell	29,800 -33,400	-53%	-$621K	﹤0.01%	8910
2020 Q4	$923K	Sell	63,200 -24,900	-28%	-$330K	﹤0.01%	6960
2020 Q3	$1.25M	Buy	88,100 +63,800	+263%	+$975K	﹤0.01%	5627
2020 Q2	$357K	Buy	+24,300	New	+$247K	﹤0.01%	7634

Citadel Advisors's GNMK Position: Q2 2021 in Review

Citadel Advisors sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 443,189 shares — an estimated $10.6M sold.

Citadel Advisors first reported a position in GNMK in Q3 2013 and held it in 20 quarters. The position peaked at $11.1M in Q2 2017. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.

Citadel Advisors reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
Citadel Advisors sold 443,189 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $10.6M.
Citadel Advisors first reported a position in GenMark Diagnostics, Inc in Q3 2013 and held it in 20 quarters.
Citadel Advisors's GenMark Diagnostics, Inc position peaked at $11.1M in Q2 2017.
0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.

Based on Citadel Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.